Samalin Investment Counsel LLC Lowers Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Samalin Investment Counsel LLC lessened its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 40.1% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 523 shares of the biopharmaceutical company’s stock after selling 350 shares during the period. Samalin Investment Counsel LLC’s holdings in Regeneron Pharmaceuticals were worth $275,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in the stock. Activest Wealth Management grew its stake in shares of Regeneron Pharmaceuticals by 110.5% in the 1st quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 21 shares during the last quarter. Costello Asset Management INC acquired a new stake in shares of Regeneron Pharmaceuticals during the first quarter worth $27,000. Saudi Central Bank acquired a new stake in shares of Regeneron Pharmaceuticals during the first quarter worth $27,000. Migdal Insurance & Financial Holdings Ltd. purchased a new position in Regeneron Pharmaceuticals in the 2nd quarter valued at $31,000. Finally, Colonial Trust Advisors acquired a new position in Regeneron Pharmaceuticals in the 1st quarter valued at $32,000. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Trading Down 0.4%

Shares of Regeneron Pharmaceuticals stock opened at $654.74 on Tuesday. The company has a 50-day moving average of $589.52 and a two-hundred day moving average of $568.29. Regeneron Pharmaceuticals, Inc. has a 12-month low of $476.49 and a 12-month high of $834.42. The company has a current ratio of 4.06, a quick ratio of 3.72 and a debt-to-equity ratio of 0.09. The stock has a market cap of $69.39 billion, a PE ratio of 15.68, a price-to-earnings-growth ratio of 2.03 and a beta of 0.31.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 EPS for the quarter, topping the consensus estimate of $9.73 by $2.10. The business had revenue of $3.75 billion for the quarter, compared to analyst estimates of $3.57 billion. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The company’s quarterly revenue was up .9% on a year-over-year basis. During the same quarter in the previous year, the company earned $12.46 EPS. On average, research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 5th. Investors of record on Thursday, November 20th will be given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 0.5%. The ex-dividend date is Thursday, November 20th. Regeneron Pharmaceuticals’s payout ratio is currently 8.43%.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, VP Jason Pitofsky sold 431 shares of the firm’s stock in a transaction on Friday, November 7th. The stock was sold at an average price of $651.43, for a total transaction of $280,766.33. Following the completion of the transaction, the vice president owned 4,233 shares of the company’s stock, valued at approximately $2,757,503.19. This trade represents a 9.24% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Christine A. Poon sold 6,500 shares of the company’s stock in a transaction on Wednesday, October 29th. The shares were sold at an average price of $654.27, for a total value of $4,252,755.00. Following the completion of the sale, the director owned 2,352 shares in the company, valued at $1,538,843.04. This represents a 73.43% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 7.02% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several analysts have recently commented on the stock. Citigroup raised their target price on shares of Regeneron Pharmaceuticals from $660.00 to $700.00 and gave the stock a “buy” rating in a research note on Wednesday, October 29th. Jefferies Financial Group raised their price objective on shares of Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the company a “buy” rating in a research report on Wednesday, August 27th. Royal Bank Of Canada lifted their price objective on Regeneron Pharmaceuticals from $704.00 to $708.00 and gave the company a “sector perform” rating in a report on Wednesday, October 29th. Wells Fargo & Company increased their target price on Regeneron Pharmaceuticals from $580.00 to $615.00 and gave the stock an “equal weight” rating in a research note on Wednesday, October 29th. Finally, Guggenheim raised their price target on Regeneron Pharmaceuticals from $815.00 to $865.00 and gave the company a “buy” rating in a report on Wednesday, October 29th. Three research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $796.57.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.